MYNZ

Company Overview — What Does MAINZ BIOMED N.V. Do?

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany. MAINZ BIOMED N.V. (MYNZ) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Guido Baechler and employs approximately 30 people. With a market capitalization of $11M, MYNZ is one of the notable companies in the Healthcare sector.

MAINZ BIOMED N.V. (MYNZ) Stock Rating — Avoid (April 2026)

As of April 2026, MAINZ BIOMED N.V. receives a Avoid rating with a composite score of 23.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.MYNZ ranks #4,313 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MAINZ BIOMED N.V. ranks #788 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MYNZ Stock Price and 52-Week Range

MAINZ BIOMED N.V. (MYNZ) currently trades at $0.84. The stock gained $0.02 (2.1%) in the most recent trading session. The 52-week high for MYNZ is $5.34, which means the stock is currently trading -84.2% from its annual peak. The 52-week low is $0.55, putting the stock 54.1% above its annual trough. Recent trading volume was 5.3M shares, reflecting moderate market activity.

Is MYNZ Overvalued or Undervalued? — Valuation Analysis

MAINZ BIOMED N.V. (MYNZ) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 16.47x, versus the sector average of 2.75x. The price-to-sales ratio is 4.92x, compared to 1.66x for the average Healthcare stock.

At current multiples, MAINZ BIOMED N.V. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

MAINZ BIOMED N.V. Profitability — ROE, Margins, and Quality Score

MAINZ BIOMED N.V. (MYNZ) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -10106.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -1217.2% versus the sector average of -33.1%.

On a margin basis, MAINZ BIOMED N.V. reports gross margins of 72.6%, compared to 71.5% for the sector. The operating margin is -3005.0% (sector: -66.1%). Net profit margin stands at -3018.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MYNZ Debt, Balance Sheet, and Financial Health

MAINZ BIOMED N.V. has a debt-to-equity ratio of 730.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.50x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $1M. Cash and equivalents stand at $6M.

MYNZ has a beta of 1.29, meaning it is more volatile than the broader market — a $10,000 investment in MYNZ would be expected to move 29.4% more than the S&P 500 on any given day. The stability factor score for MAINZ BIOMED N.V. is 20/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

MAINZ BIOMED N.V. Revenue and Earnings History — Quarterly Trend

In TTM 2026, MAINZ BIOMED N.V. reported revenue of $537,080 and earnings per share (EPS) of $-2.70. Net income for the quarter was $-16M. Gross margin was 72.6%. Operating income came in at $-16M.

In FY 2025, MAINZ BIOMED N.V. reported revenue of $537,080 and earnings per share (EPS) of $-2.70. Net income for the quarter was $-16M. Gross margin was 72.6%. Revenue grew -68.9% year-over-year compared to FY 2024. Operating income came in at $-16M.

In FY 2024, MAINZ BIOMED N.V. reported revenue of $2M and earnings per share (EPS) of $-22.36. Net income for the quarter was $-22M. Gross margin was 33.3%. Revenue grew 92.8% year-over-year compared to FY 2023. Operating income came in at $-19M.

In FY 2023, MAINZ BIOMED N.V. reported revenue of $895,479 and earnings per share (EPS) of $-64.76. Net income for the quarter was $-26M. Gross margin was 56.9%. Revenue grew 69.0% year-over-year compared to FY 2022. Operating income came in at $-27M.

Over the past 7 quarters, MAINZ BIOMED N.V. has demonstrated a growth trajectory, with revenue expanding from $383,185 to $537,080. Investors analyzing MYNZ stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MYNZ Dividend Yield and Income Analysis

MAINZ BIOMED N.V. (MYNZ) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MYNZ Momentum and Technical Analysis Profile

MAINZ BIOMED N.V. (MYNZ) has a momentum factor score of 8/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 62/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 51/100 reflects moderate short selling activity.

MYNZ vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, MAINZ BIOMED N.V. (MYNZ) ranks #788 out of 838 stocks based on the Blank Capital composite score. This places MYNZ in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MYNZ against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MYNZ vs S&P 500 (SPY) comparison to assess how MAINZ BIOMED N.V. stacks up against the broader market across all factor dimensions.

MYNZ Next Earnings Date

No upcoming earnings date has been announced for MAINZ BIOMED N.V. (MYNZ) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MYNZ? — Investment Thesis Summary

The quantitative profile for MAINZ BIOMED N.V. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Momentum is weak at 8/100, a headwind for near-term performance. High volatility (stability score 20/100) increases portfolio risk.

In summary, MAINZ BIOMED N.V. (MYNZ) earns a Avoid rating with a composite score of 23.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MYNZ stock.

Related Resources for MYNZ Investors

Explore more research and tools: MYNZ vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MYNZ head-to-head with peers: MYNZ vs AZN, MYNZ vs SLGL, MYNZ vs VMD.